Top in cardiology: Anger may raise CVD risk; cardiovascular-kidney-metabolic syndrome

A laboratory-based, randomized controlled experimental study revealed that anger can negatively impact vascular endothelial health and function, potentially raising heart disease risk.

“We saw that evoking an angered state led to blood vessel dysfunction, though we don’t yet understand what may cause these changes,” Daichi Shimbo, MD, a professor of medicine at the Columbia University Irving Medical Center, said in a press release from the American Heart Association. “Investigation into the underlying links between anger and blood vessel dysfunction may help identify effective intervention targets for people at increased risk of cardiovascular events.”

It was the top story in cardiology last week.

In another top story, researchers found that more than 70% of the U.S. population is estimated to have stage 1 to 3 cardiovascular-kidney-metabolic syndrome.

“The high prevalence of multimorbidity that defines the newly described CKM syndrome highlights the urgent need for public health intervention to optimize the health of individuals in the United States,” Abdul Mannan Khan Minhas, MD, a clinical fellow in preventive cardiology at Baylor College of Medicine, and colleagues wrote.

Read these and more top stories in cardiology below:

Feelings of anger disrupt endothelial function, which may raise heart disease risk

Disruptions in endothelial function caused by brief bouts of elicited anger may be an early predictor of heart disease, but the underlying mechanism remains unclear, researchers reported. Read more.

Most US adults estimated to have subclinical cardiovascular-kidney-metabolic syndrome

More than 70% of the overall U.S. population is estimated to have subclinical cardiovascular-kidney-metabolic syndrome, according to a research letter published in the Journal of the American College of Cardiology. Read more.

Gene therapy improves symptoms for patients with ‘no-option’ treatment-resistant angina

Gene therapy improved exercise capacity and blood flow and reduced chest pain occurrence and nitroglycerine use for patients with advanced ischemic heart disease, a speaker reported. Read more.

Study questions practice of routine fasting before cardiac catheterization

Patients not required to fast before cardiac catheterization reported higher overall postprocedural satisfaction with no periprocedural adverse events, a speaker reported. Read more.

Ninerafaxstat improves symptoms, quality of life in nonobstructive HCM

For patients with nonobstructive hypertrophic cardiomyopathy, ninerafaxstat, a novel cardiac mitotrope, safely improved heart failure symptoms during a 12-week period vs. placebo, a speaker reported. Read more.